Articles tagged with Nanomedicine
Researchers at Tel Aviv University developed a drug delivery system based on lipid nanoparticles that utilize RNA to boost personalized cancer care. The nanodrug enhances chemotherapy effectiveness and reinvigorates the immune system, increasing sensitivity to cancer cells.
The team used a microscale diffuser to distribute ultrasound waves uniformly, reducing the risk of over-exposure or under-exposure. The device successfully stimulated cells in human embryonic kidney cells and neuron cells, as well as mice, with improved targeting.
A new fabric developed by MIT engineers can detect subtle heartbeat features and the direction of sudden sounds, enabling real-time monitoring of vital signs. The fabric works like a microphone, converting sound vibrations into electrical signals.
Researchers at Massachusetts General Hospital found that using nanomedicines at lower, more frequent doses can normalize the tumor microenvironment and improve cancer treatments. The study showed that this approach can help correct abnormalities that protect tumors and improve blood vessel function and immune activation within a tumor.
Researchers at the University of South Australia have developed a new way to deliver chemotherapy drugs, using liposomal formulations that target tumors more effectively. This breakthrough could improve treatment outcomes for thousands of cancer patients, reducing side effects and improving quality of life.
Researchers examine ways to target specific neurons using nanomedicine, aiming to improve treatment options for neurodegenerative diseases like Alzheimer's and Parkinson's. The study highlights the challenges of delivering drugs to specific populations of neurons in the brain.
Researchers have identified the impact of protein corona formation on nanoparticles' physiochemical and biological properties. This knowledge can be used to optimize carriers for nanomedical applications, improving the efficiency and effectiveness of biopharmaceutical delivery.
Researchers at Penn Medicine have discovered a new method to prevent the body's proteins from attacking treatment-carrying nanoparticles, allowing for more effective delivery of therapies. By coating nanoparticles with natural suppressors of complement activation, such as Factor I, the team has shown improved protection against immune ...
A new targeted nanomedicine treatment developed at the University of Chicago has shown promise in reducing vascular lesions caused by atherosclerosis. The treatment delivers medicine directly to inflamed cells, targeting the site of inflammation and inhibiting stenosis, the remodeling of vascular tissue that causes it to close off.
Researchers have developed a ferritin-based nanomedicine that targets diverse leukemia types, improving therapeutic efficacy and reducing toxicity. The nanomedicine delivers arsenic to leukemia cells, enhancing killing effects while minimizing harm to normal tissues.
Researchers created polymersomes that target highly invasive cancer cells, delivering anticancer drugs and preventing metastasis. The nanomachines showed strong antitumor effects in breast cancer models, inhibiting lung metastasis and prolonging survival.
A new antibody delivery technology enhances anti-PD-L1 antibody accumulation in glioblastoma by 33-fold, achieving a 60% complete response rate with long-term immune memory. The technology also suppresses immune-related adverse events.
Researchers developed an AI tool that can quickly and accurately identify suspicious proteins in the body by analyzing their movements. The method, known as diffusional fingerprinting, uses machine learning algorithms to predict protein behavior with over 90% accuracy.
A new microneedle patch containing cerium nanoparticles has been designed to combat both primary causes of baldness: oxidative stress and insufficient circulation. The patch showed faster hair regrowth in a mouse model compared to a leading treatment.
Researchers have discovered that dendrimer tentacles can avoid detection by the complement system, part of our immune system. This could lead to developing a new system for delivering drugs into the body without triggering an immune response.
Researchers have developed poly-ion complex (PIC) nanomicelles loaded with CPT1A inhibitors to deliver drugs into brain cells, reducing fatty acid oxidation and improving treatment for glioblastoma. The delivery system successfully increased cellular concentration of the cargo and biological activity.
Researchers explore integrating reactive oxygen species generation and prodrug activation to enhance cancer therapy. Stimuli-responsive nanomedicines can target tumors, generating ROS that activate drug release, offering promising synergetic therapy strategies.
Researchers explore connections between preclinical and clinical modeling to develop unique animal-based disease models. Integration of active-targeting ligands and smart materials enhances nanomedicine functionalities, paving the way for new-concept nanoparticle-based drugs.
Research by MSU's Morteza Mahmoudi suggests that Covid-19 vaccines developed with nanomedicine may have different efficacies for men and women due to sex-based differences. The study highlights the importance of considering sex in vaccine development and research, particularly in using nanomedicines.
Researchers developed polymeric nano-micelles that target specific levels of c-Myc expression, a key factor in cancer cell proliferation. The study showed varying efficacy depending on tumor c-Myc expression levels, with higher expression associated with better antitumor activity.
Researchers have developed a unique combination of microscopy techniques to study the biological effects of nanoparticles and their interaction with human plasma. This approach allows for an unprecedented view of the nanoparticle's 'corona', also known as its biological 'crown', which contains clues about how nanoparticles interact wit...
Researchers have developed ultra-small nanomedicines that stably deliver oligonucleotides to refractory cancers, such as brain tumors and pancreatic cancer. These nanomedicines use Y-shaped block copolymers and nucleic acid drugs, achieving high permeability in cancer tissues and stability in the bloodstream.
The authors review future directions of nanomedicine development focusing on the mechanism of nanoparticle entry into tumors. Designing better nanoparticles to achieve efficient clinical transformation can be informed by a deep understanding of the mechanism of nanoparticle entry or the mode of action.
The Kawasaki Institute of Industrial Promotion has opened a new website for Project COINS, which aims to establish an in-body hospital network by 2045. The initiative is part of the Center of Innovation Program (COI) and will focus on creating innovative healthcare and medical technologies.
Researchers at Eindhoven University of Technology prove the Velcro method enhances selectivity in drug particle binding based on receptor number and strength. This allows precise targeting of diseased cells while distinguishing them from healthy ones.
The BIO Integration Virtual Conference Series July 2020 examines the intersection of nanomedicine, biology, and technology. Key topics include the integration of naturally occurring bioactive compounds into nanomedicine and nanoparticles meditated LncRNA silencing for effective cancer radiotherapy.
Scientists propose advanced engineering strategies for gas-releasing nanomedicines to enhance bioavailability and safety of therapeutic gases. These nanomedicines aim to maximize profits in gas therapy by providing controlled release and targeting cancer cells.
A nanomedicine expert proposes a cancer care model for managing COVID-19, focusing on early detection, regular monitoring, and targeted treatment. This approach could improve patient outcomes by providing systematic management of the pandemic.
Researchers at Stockholm University discovered engineered silica particles can reduce food efficiency, leading to lower weight gain and improved metabolic profiles in mice. The study suggests these particles could be used to treat obesity and diabetes in humans.
Researchers developed an exosome-based nanomedicine that increases tumor accumulation and penetration after intravenous administration. The biocompatible nanomedicines combine natural biomaterials with synthetic nanoparticles, demonstrating potential for improved anticancer drug efficacy.
Researchers have developed a nanotherapeutic called S-HDL that reduces inflammation in blood vessels, halting plaque accumulation and vessel wall inflammation in animal models. The new production method boosts therapeutic yields by up to 80-fold, paving the way for human application.
Lauren Sciences LLC has received an AU$1 million grant from FightMND to advance its development of LAUR-301, a novel V-Smart Nanomedicine for ALS. The therapy aims to protect motor neurons and induce neuro-restoration, slowing or reversing the disease.
Researchers from NUS discovered that certain nanoparticles can widen the gap between blood vessel cells, making it easier for cancer cells to spread. This phenomenon, named NanoEL, accelerates tumor growth and causes circulating cancer cells to escape from blood circulation.
Recent review highlights latest advances in precise nanomedicine for intelligent cancer therapy, exploring metallofullerenol nanoparticles, supramolecular chemo-therapy, and DNA nanorobots. These strategies aim to improve cancer imaging and therapeutic applications while understanding nanotoxicity.
The ALS Association granted Lauren Sciences LLC its third award for developing LAUR-301, a V-Smart Nanomedicine for ALS. LAUR-301 aims to deliver GDNF across the blood-brain barrier and induce neuro-restoration in all ALS patients.
Research by Prof. Dr. Prasad Shastri at the University of Freiburg found that cancer cell membrane stiffness affects nanoparticle internalization; increasing stiffness enhances polymer nanoparticle entry through pathways rich in cholesterol.
Researchers created a nanomedicine platform that uses near-infrared imaging to detect tumors and kill residual cancer cells using phototherapy. The platform has shown great precision and thoroughness in cancer treatment, with promising results in mouse models.
A $3 million collaboration between the University of Liverpool and Johns Hopkins University aims to develop novel, long-acting HIV medicines. The project seeks to create implantable technologies that can deliver drugs for weeks or months, potentially improving patient adherence.
Lauren Sciences LLC has received the second grant from Voices Against Brain Cancer to continue developing LAUR-401, its innovative V-Smart Nanomedicine for Glioblastoma Multiforme. The award confirms the successful development of LAUR-401 and anticipates its potential as a transformative therapeutic for brain cancer patients.
Lauren Sciences will use the grant to customize LAUR-301 with neurotrophic factor and deliver it to disease sites in central nervous system ALS mice. The company aims for LAUR-301 to enter human clinical trials and become a transformative V-Smart TM Nanomedicine for treating ALS.
The special focus issue brings together experts from various fields to discuss the past, present, and future of nanomedicine. It addresses current debates and future perspectives on nanomedical research, including social, ethical, and safety aspects.
The European Nanomedicine Characterization Laboratory (EU-NCL) aims to bring safe and efficient nanotherapeutics faster to patients. EU-NCL partners with international reference facilities to harmonize analytical protocols, providing a trans-disciplinary testing infrastructure for preclinical characterization.
V-Smart Nanomedicine for glioblastoma multiforme (GBM) will target and deliver a known chemotherapeutic across the blood brain barrier, providing an effective new treatment option. The grant supports the development of this transformative therapeutic for brain cancer patients.
A special focus issue in Nanomedicine examines the intersection of nanomedicine and regenerative medicine, showcasing advancements in nanotopography, nanofunctionalization, and stem cell research. The field of nanoregeneration has grown exponentially over the last 15 years, with potential applications in drug discovery and cell targeting.
Researchers developed targeted biodegradable nano-drones that deliver an anti-inflammatory drug to fat deposits in arteries, successfully restructuring atherosclerotic plaques to make them more stable. The treatment reduced reactive oxygen species, increased collagen, and decreased plaque necrotic core.
The FDA has approved dozens of nanodrugs without a formal definition, leading to case-by-case examination and nonbinding guidance. This complexity hinders the development of generic nanodrugs, potentially delaying price savings for patients.
Researchers found that a particle size of 50 nm is optimal for anti-cancer nanomedicines, with enhanced performance in vivo and improved tumor inhibition.
A five-year, $1.15 million grant supports Northeastern's 'CaNCURE' program, offering 75 undergraduate students hands-on research experience with leading cancer nanomedicine experts. The program aims to address cancer disparities and motivate students to pursue careers in cancer research and clinical practice.
Researchers will use radioactive labelling to track where key materials used in nanomedicines accumulate in the body. This study aims to inform regulation and development of safer nanomedicine options for chronic conditions.
Researchers developed biodegradable nanoparticles that selectively target and resolve inflammation, potentially treating atherosclerosis and neurodegenerative diseases. The nanoparticles release an inflammation-resolving peptide drug, promoting tissue repair and reducing chronic inflammation.
Combining antiangiogenesis drugs with smaller nanomedicines may enhance treatment effectiveness for certain cancers. Vascular normalization temporarily decreases tumor blood vessel diameter, improving drug penetration of smaller particles but not larger molecules.
A realistic look at nanomedicine reveals both promise and perils. While dozens of nano health care products are in use, the field also poses risks of nanoparticle toxicity and unintended interactions.
Researchers at the University of Melbourne have successfully tracked a quantum atom inside a living human cell, paving the way for new drug discovery methods. The sensor detects biological processes at a molecular level, providing critical information about drug delivery and uptake.
The Canadian Institutes of Health Research has awarded $16 million in funding for seven new research projects on regenerative medicine and nanomedicine. These studies aim to develop new therapies and approaches to treat illnesses and diseases, ultimately improving patient outcomes.
The summit explored ways to use nanotechnology in medical imaging and therapy, focusing on targeting diseases such as cancer, neurological conditions, and cardiovascular disease. Experts discussed regulatory frameworks, design considerations, and future directions for this rapidly evolving field.
The University of Texas Health Science Center at Houston's UT nanomedicine project will be tested in space as part of a nationwide competition. The experiment aims to study the diffusion of micro nanoparticles through tiny microchannels, which could aid in developing implantable devices for controlled drug release.
The University of Copenhagen has received funding to establish a new center for pharmaceutical nanotechnology and nanotoxicology, aiming to optimize delivery systems and therapeutic benefits. The center will focus on rational design of nanotechnology materials and tools to improve therapeutic benefit-to-risk ratio.
The Mattel UCLA NanoPediatrics Program will explore the future of personalized medicine for children using nanotechnology. Researchers will develop new diagnostic tools and treatments to improve health outcomes for young patients.
Researchers developed a multistage delivery system to improve injectable drug efficacy, targeting diseased cells and releasing therapeutics in a controlled manner. The system uses mesoporous silicon particles to circumvent biobarriers and deliver diagnostic agents or therapeutic agents.
Researchers at UT Health Science Center have developed a smart particle insulin release system that detects blood sugar spikes and releases insulin to counteract them. The system, which consists of a blood sugar sensing protein and liposomes loaded with insulin, stabilized blood sugar levels in animal models for up to six hours.